EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies

Bob T Li, Leena Gandhi, Vignesh Ravichandran, Benjamin Besse, Julien Mazières, Geoffrey I Shapiro, Valentina Boni, Saiama N Waqar, Haeseong Park, David I Quinn, Alejandro Martinez, Salomon M Stemmer und 13 weitere

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2025.09.009 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Bob T Li und 24 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Quinolines, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Memorial Sloan Kettering Cancer Center Marie-Josée and Henry R Kravis Center for Molecular Oncology, Cycle for Survival.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: ERBB2 mutations are oncogenic drivers in 2% to 4% of lung cancers and potentially actionable using HER2 tyrosine kinase inhibitors. PATIENTS AND METHODS: Patients with advanced ERBB2-mutant lung cancer entered 2 phase 2 studies (PUMA-NER-4201 [4201]; PUMA-NER-5201 [SUMMIT]). Patients received neratinib (monotherapy 4201; monotherapy SUMMIT), or neratinib with weekly temsirolimus (combination 4201), or trastuzumab every 3 weeks (combination SUMMIT). Protocol-defined endpoints common to both studies were analyzed. Exploratory genomic analyses were conducted. CLINICALTRIALS: gov: NCT01827267; NCT01953926. RESULTS: Sixty patients in 4201 (neratinib, n = 17; neratinib plus temsirolimus, n = 43) and 78 in SUMMIT (neratinib, n = 26; neratinib plus trastuzumab, n = 52) received study treatment. Objective response rates were 0% (95% confidence interval [CI], 0.0-19.5; 4201) and 3.8% (95% CI, 0.1-19.6; SUMMIT) with neratinib, 14.0% (95% CI, 5.3-27.9) with neratinib plus temsirolimus, and 9.6% (95% CI, 3.2-21.0) with neratinib plus trastuzumab. Five patients whose tumors harbored ERBB2 exon 20 insertion, L755P and D769Y missense mutations, and a novel ERBB2-SHC1 fusion had responses ≥ 1 year (neratinib monotherapy, n = 1; SUMMIT; neratinib plus temsirolimus, n = 2; neratinib plus trastuzumab, n = 2). Grade ≥ 3 treatment-related adverse events occurred in 23.5% (4201) and 34.6% (SUMMIT) of neratinib-treated patients, 37.2% of patients treated with neratinib plus temsirolimus, and 48.1% of patients treated with neratinib plus trastuzumab. CONCLUSION: Single-agent neratinib has limited activity in ERBB2-mutated lung cancers. Combinations with temsirolimus or trastuzumab did not markedly improve overall outcomes, producing durable responses in a limited subset of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesQuinolinesLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMutationAdenocarcinoma of LungHumansFemaleMaleMiddle AgedAgedTrastuzumabAdultAged, 80 and overSirolimus

Stichwörter der Autor:innen

ERBB2 mutationNonsmall-cell lung cancerTyrosine kinase inhibitorUncommon mutations

Substanzen

neratinibErb-b2 Receptor Tyrosine KinasesQuinolinesERBB2 protein, humanTrastuzumabtemsirolimusSirolimus

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, NY.
  • Dana-Farber Cancer Institute, Boston, MA.
  • Gustave Roussy, Paris Saclay University, Villejuif, France.
  • Hôpital Universitaire de Toulouse, Université Paul Sabatier, Toulouse, France.
  • NEXT Madrid, University Hospital Quironsalud, Pozuelo de Alarcón, Madrid, Spain.
  • Washington University School of Medicine in St Louis, St. Louis, MO.

Förderung

  • NCI NIH HHS
  • Memorial Sloan Kettering Cancer Center Marie-Josée and Henry R Kravis Center for Molecular Oncology
  • Cycle for Survival
  • Puma Biotechnology
  • National Institutes of Health

Zitieren

APA

Li, B. T., Gandhi, L., Ravichandran, V., Besse, B., Mazières, J., Shapiro, G. I., Boni, V., Waqar, S. N., Park, H., Quinn, D. I., Martinez, A., Stemmer, S. M., Cortot, A. B., Barlesi, F., Quoix, E., Burkard, M. E., Selcuklu, S. D., Hunt, C., Donoghue, M. T. A., …, & Jänne, P. A. (2025). Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.09.009

Vancouver

Li BT, Gandhi L, Ravichandran V, Besse B, Mazières J, Shapiro GI, et al. Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.09.009

BibTeX
@article{Li2025,
  author = {Li, Bob T and Gandhi, Leena and Ravichandran, Vignesh and Besse, Benjamin and Mazières, Julien and Shapiro, Geoffrey I and Boni, Valentina and Waqar, Saiama N and Park, Haeseong and Quinn, David I and Martinez, Alejandro and Stemmer, Salomon M and Cortot, Alexis B and Barlesi, Fabrice and Quoix, Elisabeth and Burkard, Mark E and Selcuklu, S Duygu and Hunt, Casey and Donoghue, Mark T A and Kris, Mark G and Bebchuk, Judith and Eli, Lisa D and McCulloch, Leanne and Solit, David B and Jänne, Pasi A},
  title = {Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2025.09.009}
}
Kostenlos starten →